Upload
cardiacinfo
View
1.977
Download
1
Embed Size (px)
DESCRIPTION
Citation preview
Diagnosis and Management of
Congestive Heart Failure
David Putnam, MD
Albany Medical College
• Coronary heart disease mortality has declined steadily since 1972
• Hospitalizations rates for CHF have increased
Incidence of CHF
• Common medical condition that afflicts 4.8 million people in the US
• Approximately 2% of the US population has CHF
• 400,000 to 700,000 new cases per year
• Prevalence increases with age
• Up to 20 million people may have asymptomatic LV dysfunction
Congestive Heart Failure
• Pathophysiologic state in which cardiac output is inadequate to meet the metabolic needs of the body
• Complex clinical syndrome that can result from any cardiac disorder that impairs the ability of the ventricle to eject blood
Historical Perspective of CHF
• Dropsical condition
• Central cardiac pump problem
• Circulatory dysfunction
• Disorder of renal function
• Complicated milieu of pump dysfunction, remodeling, humoral perturbation and subsequent circulatory insufficiency
Syndrome of CHF in the 1990s in US
• CAD most common cause ( >70% )
• Systemic and/or pulmonary congestion infrequent
• Diastolic dysfunction common in the elderly
• Sudden death frequent ( > 50% )
CHF: Survival
• Average 5-year survival 50%
• Survival in women better than in men
• Risk of death is 5 to 10% annually in patients with mild symptoms
• Risk of death is 30 to 40% annually in patients with severe symptoms
CHF: Survival
Left Ventricular Failure
• Systolic Dysfunction
• Diastolic Dysfunction
• Systolic and Diastolic Dysfunction
CHF: Systolic Dysfunction
• Causative Factor
A. Loss of Muscle
B. Pressure Overload
C. Volume Overload
D. Decreased contractility
• Example
A. Myocardial Infarct
B. Hypertension
C. Valvular regurgitation
D. Dilated cardiomyopathy
CHF: Diastolic Dysfunction
• Causative Factor
A. Delayed relaxation
B. Restricted filling
C. Reduced filling time
(tachycardia)
• Example
A. Ischemia
B. Hypertrophic cardiomyopathy
C. Mitral stenosis
CHF: Diastolic Dysfunction
• Very common
• 20 to 40% of all new cases of CHF
• Incidence increases with age
CHF: Disease Process
CHF: Ventricular Dysfunction
CHF: Hemodynamic Abnormalities
CHF: Compensatory Mechanisms
CHF: Clinical PresentationCardinal Manifestations
• Dyspnea
• Fatigue
• Fluid retention ( pulmonary and peripheral edema )
CHF: Steps in Evaluation
• Rule out precipitating causes
• Determine LVEF
• Systolic vs. diastolic dysfunctin
• Rule out CAD/myocardial ischemia
• Rule out significant ventricular arrhythmias
• Functional capacity
CHF: Precipitating Causes
• Poor compliance with meds or diet
• Alcohol abuse
• Uncontrolled HTN
• Ischemia/MI
• Arrhythmias, e.g., atrial fibrillation
• Infection, anemia, thyrotoxicosis
• Renal dysfunction
• Medications
CHF: Physical Findings
• Pulsus alternans
• Elevated jugular venous pressure
• Displaced cardiac apical impulse
• Third heart sound
• Pulmonary rales
• Hepatomegaly
• Peripheral edema
CHF: Lab Tests
CHF: Lab Tests
Diagnosis of CHFRoutine Tests
• ECG
• Chest x-ray
• Echocardiogram
CHF: ECG
CHF: CXR
• Cardiomegaly
• Vascular redistribution
• Kerley B lines
• Interstitial edema
• Peri-bronchial “cuffing”
• Effusions
Congestive Heart Failure
CHF: Echocardiogram
• Chamber enlargement
• Wall motion abnormalities
• Diminished ejection fraction
• Possible LVH
• Possible valvular problems
• Assess diastolic dysfunction
Echocardiogram
Dilated Cardiomyopathy
Hypertrophic Cardiomyopathy
CHF: Additional Testing
• MUGA scan
• Exercise stress test
• Cardiac catheterization
• Holter monitor
CHF: Treatment Goals
• Improve symptoms
A. Enhance well-being and quality of life
B. Increase exercise tolerance
• Improve survival
A. Prevent progressive heart failure
B. Prevent sudden death
C. Prevent thromboembolic episodes
CHF: Medical Management
• Diuretics
• Digitalis
• ACE Inhibitors
• Beta Blockers
• Spironolactone
CHF: Diuretics
• Reduce volume overload
• Reduce sodium overload
• Preload reduction
CHF: Diuretics
Advantages
• Highly effective in most classes
• Essential with fluid retention
• Well tolerated, simple to use
Disadvantages
• Electrolyte abnormalities
• Hypovolemia, hypotension, renal dysfunction
• Activation of neurohormaonal system
CHF: Diuretics
• Elimination of symptoms and/or signs of congestion
• Avoid volume depletion
A. Postural hypotension
B. Increase in heart rate
C. Increase in BUN/Cr
D. Neuroendocrine activation
Diuretics
Thiazide Diuretics
• HCTZ
• Chlorthalidone
• Metolazone
Loop Diuretics
• Furosemide
• Torsemide
Potassium Sparing Diuretics
• Spironolactone
• Triamterene
• Amiloride
CHF: SpironolactoneRALES Study
• Spironolactone 25 mg/day in Class III or IV patients in addition to ACE and loop diuretics
• 30% reduction in mortality
• 31% reduction in cardiac mortality
• Anti-aldosterone effect
Pitt B. NEJM 1999;341:709-717
CHF: Digoxin
• Improves rest and exercise hemodynamics
• Attenuates neurohormal abnormalities
• Improves symptoms
• May result in fewer hospitalizations and ER visits
• Has unknown effects on mortality
CHF: Digoxin
• Useful in patients with CHF and supraventricular arrhythmias
• Useful in patients with systolic dysfunction
• Disadvantages include:
A. Narrow Rx range
B. Synergistic toxicity with hypokalemia
C. Drug interactions
D. Possible arrhythmogenesis
CHF: ACE Inhibitors
• Improve hemodynamic status
• Attenuate neurohumoral abnormalities
• Improve symptoms
• Reduce incidence of hospitization
• Slow progression
• Reduce mortality
CHF: ACE Inhibitors
Neurohormonal Changes
• Decreased angiotensin II
• Increased bradykinin
• Decreased or no change in aldosterone
• Decreased norepinephrine
CHF: ACE Inhibitors
Reduction in Sudden Death/Potential Mechanisms
• Increase in serum/total body potassium
• Decreased adrenergic stimulation
• Reduced heart size and decrease in ventricular hypertrophy
• Prevention of myocardial ischemia
• Prevention of progressive myocardial damage
CHF: FDA Approved ACE Inhibitors
• Captopril
• Enalapril
• Lisinopril
• Quinapril
• Trandolapril
• Fosinopril
CHF: ACE Inhibitor Doseages
Captopril
Enalapril
Lisinipril
Quinapril
• Start: 6.25 bid/tid
• Usual: 6.25-50 bid/tid
• Start: 2.5 qd/bid
• Usual: 2.5-10 bid
• Start: 2.5-5 qd
• Usual: 5-20 qd
• Start: 5 bid
• Usual 10-20 bid
ELITE IIELITE II Primary Endpoint: All-Cause MortalityPrimary Endpoint: All-Cause Mortality
00 100100 200200 300300 400400 500500 600600 700700
Days of Follow-upDays of Follow-up
0.00.0
0.20.2
0.40.4
0.60.6
0.80.8
1.01.0
Pro
babi
lity
of S
urvi
val
Pro
babi
lity
of S
urvi
val
LosartanLosartanCaptopril Captopril
Hazard Ratio (95-7% C.I.) = 1.13 (0.95-1.35) P = 0.16Hazard Ratio (95-7% C.I.) = 1.13 (0.95-1.35) P = 0.16
Lancet Lancet 2000;355:1582-872000;355:1582-87
ELITE IIELITE IIWithdrawal for Adverse Experience (Excluding Death)Withdrawal for Adverse Experience (Excluding Death)
0
5
10
15
20
Any AE Drug-RelatedAE
Cough HF
% o
f P
atie
nts
Losartan (N=1578)Captopril (N=1574)
******** p p0.001 between 0.001 between groupsgroups
****
****
Lancet Lancet 2000;355:1582-872000;355:1582-87
ELITE IIELITE IIDiscussionDiscussion
• Losartan was not superior to captopril in improving survival in elderly heart-failure patients, but was significantly better tolerated.
• Based on extensive randomized, placebo-controlled observations, ACE inhibitors should be the initial treatment for heart failure, although angiotensin II receptor antagonists may be useful to block the renin angiotensin aldosterone system when ACE inhibitors are not tolerated.
Lancet Lancet 2000;355:1582-872000;355:1582-87
CHF: Beta Blockers
• Acutely depresses myocardial function (pharmacological)
• Chronically improves myocardial function (biological)
CHF: Beta Blockers
• Primary mechanism is inhibition of down regulation of beta receptors
• Additional mechanismsA. Restore receptor densityB. Protect against cardiotoxicity of
catecholeaminesC. Improve systolic/diastolic function in
ischemic myocardium
Beta Blockers
• First Generation: Beta 1 and Beta 2
Propranolol/Timolol
• Second Generation: Beta 1
Metoprolol/Atenolol
• Third Generation: Vasodilating Properties
Carvedilol
CHF: Beta Blockers
Improve symptoms and clinical class
• Degree of benefit appears to relate to degree of disability before treatment
Reduce Mortality
• 5 trials with metoprolol/bisoprolol
• 5 trials with carvedilol
CHF: Metoprolol vs. Carvedilol
• Randomized, double-blind comparison
• 150 patients followed for 12 months
• Class II, III, IV
• LVEF <=35%
• Greater improvement in cardiac function with Carvedilol
Circulation 2000(AUG);102:546-551.
CHF: Beta Blockers
• Should be used in all stable Class II/III patients unless contraindicated
• Treatment should not be initiated in patients with acutely decompensated CHF
• Clinical response may take 2 to 3 months
CHF: Beta Blockers
Risks of Treatment
• Hypotension
• Fluid retention and worsening CHF
• Bradycardia and heart block
CHF: Beta Blockers
• Carvedilol
• Metoprolol
• Bisoprolol
• Start: 3.125 mg bid
• Usual: 25 mg bid
• Start: 12.5-25 mg qd
• Usual: 50-100 mg bid
• Start: 1.25 mg qd
• Usual: 5-10 mg qd
CHF: IV Dobutamine
• 80 patients with class III/IV CHF
• Continuous IV Dobutamine @ 9 mcg/kg/min for 14 days
• Adverse event rate in treatment group: 85%
• Adverse event rate in placebo group: 65%
AM HRT J 1999;138:78-86
CHF: IV Dobutamine
• Continuous IV Dobutamine has never been shown to improve survivorship
• Intermittent infusion has been called into question
Ewy GA. JACC 1999;33:572-74
CHF: Diastolic Dysfunction
• Difficult to treat
• Diuretics for volume overload. Avoid volume depletion
• Prevent tachycardia
• Rate-limiting calcium channel blockers first choice
• Beta 1 beta blockers second choice
Diastolic Time and Heart Rate
CHF: Diastolic Dysfunction
Benefits of Calcium Channel Blockers
• Slowing of heart rate
• Reduction of MVO2
• Control of BP
• Regression of LVH
• Dilation of coronary microcirculation
• Amelioration of intracellular calcium overload
CHF: Diastolic Dysfunction
Benefits of Beta Blockers
• Slowing of heart rate
• Reduction of MVO2
• Control of blood pressure
• Regression of LVH
CHF: Treatment Scheme
The End
Myocardial Oxygen Consumption
CHF: ACE Inhibitors
• 18 patients with SBP 60 to 100
• At four weeks 82% of patients were tolerating Lisinipril 40 mg/day